ECCENVI Trademark

Trademark Overview


On Friday, September 3, 2021, a trademark application was filed for ECCENVI with the United States Patent and Trademark Office. The USPTO has given the ECCENVI trademark a serial number of 97010835. The federal status of this trademark filing is SECOND EXTENSION - GRANTED as of Tuesday, February 27, 2024. This trademark is owned by Neurocrine Biosciences, Inc.. The ECCENVI trademark is filed in the Pharmaceutical Products category with the following description:

pharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, tardive dyskinesia, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuro-endocrinological diseases, disorders, and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic and endocrine disorders and conditions; pharmaceutical preparations for human use for diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic a...
eccenvi

General Information


Serial Number97010835
Word MarkECCENVI
Filing DateFriday, September 3, 2021
Status731 - SECOND EXTENSION - GRANTED
Status DateTuesday, February 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4000 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 17, 2023

Trademark Statements


Goods and Servicespharmaceutical preparations for human use for treatment of Huntington's Disease, chorea associated with Huntington's Disease, schizophrenia, adjunctive treatment of schizophrenia, cognitive impairment associated with schizophrenia, epilepsy, epileptic encephalopathy with continuous spike-and-wave during sleep, SCN8A-related epilepsy with encephalopathy, focal onset seizures, tardive dyskinesia, Parkinson's Disease, adjunctive treatment of Parkinson's Disease, Major Depressive Disorder, anhedonia in Major Depressive Disorder, inadequate response to treatment in Major Depressive Disorder, dyskinetic cerebral palsy, and neuro-immunological and neuro-endocrinological diseases, disorders, and conditions; pharmaceutical preparations for the diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic and endocrine disorders and conditions; pharmaceutical preparations for human use for diagnosis, prevention and treatment of psychiatric, neurological, hormonal, genetic and endocrine diseases and disorders by gene therapy; pharmaceuticals for human use for the treatment of rare and orphan diseases, disorders and conditions of the neurological, hormonal, and endocrine systems; pharmaceutical preparations for the treatment of congenital adrenal hyperplasia

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, October 15, 2021
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameNeurocrine Biosciences, Inc.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Party NameNeurocrine Biosciences, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSan Diego, CA 92130

Trademark Events


Event DateEvent Description
Wednesday, February 28, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, February 27, 2024SOU EXTENSION 2 GRANTED
Tuesday, February 27, 2024SOU EXTENSION 2 FILED
Tuesday, February 27, 2024SOU TEAS EXTENSION RECEIVED
Wednesday, September 13, 2023NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Monday, September 11, 2023SOU EXTENSION 1 GRANTED
Monday, September 11, 2023SOU EXTENSION 1 FILED
Monday, September 11, 2023SOU TEAS EXTENSION RECEIVED
Tuesday, March 14, 2023NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Tuesday, January 17, 2023OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 17, 2023PUBLISHED FOR OPPOSITION
Wednesday, December 28, 2022NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Thursday, December 8, 2022APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, December 7, 2022TEAS/EMAIL CORRESPONDENCE ENTERED
Tuesday, December 6, 2022CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, December 6, 2022TEAS RESPONSE TO OFFICE ACTION RECEIVED
Thursday, June 9, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Thursday, June 9, 2022NON-FINAL ACTION E-MAILED
Thursday, June 9, 2022NON-FINAL ACTION WRITTEN
Wednesday, June 8, 2022ASSIGNED TO EXAMINER
Friday, October 15, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Tuesday, September 7, 2021NEW APPLICATION ENTERED